TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2434815

Group type: EXPERIMENTAL
Intervention: Org 10172 low-molecular-weight heparinoid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 30985238

Group type: EXPERIMENTAL
Intervention: Growing Pro-Social (GPS) program
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study: 28475565

Group type: EXPERIMENTAL
Intervention: Sit-stand protocols facilitated by height-adjustable workstations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual sitting (control)
Number of subjects: 26
Study: 25433821

Group type: EXPERIMENTAL
Intervention: MyTeachingPartner (MTP) coaching intervention
Number of subjects: 0
Study: 23531633

Group type: EXPERIMENTAL
Intervention: High thoracic epidural anesthesia (HTEA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard balanced general anesthesia (Control)
Number of subjects: 64
Study: 21565525

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms assessment using the Hopkins Symptom Checklist‐Depression Scale
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Maternal age, intimate partner violence, illicit drug and alcohol use during pregnancy, reproductive history
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Being very happy about the pregnancy, having emotional support from others, reporting more positive expectancies about the ability to regulate negative moods
Number of subjects: 1044
Study: 19092462

Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 57

Group type: COMPARATOR
Intervention: Topical lidocaine 2% jelly
Number of subjects: 57
Study: 16284061

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg given twice on day 1 followed by 4 days of ethinyl estradiol (EE) 20 microg in the morning and placebo at night
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 5 days
Number of subjects: 179

Group type: COMPARATOR
Intervention: Mifepristone 25 mg given twice on day 1 followed by 4 days of twice daily placebo
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 179
Study: 15124154

Group type: EXPERIMENTAL
Intervention: Korean version of the Diagnostic Interview for Genetic Studies (DIGS-K)
Number of subjects: 53
Study: 11771434

Group type: EXPERIMENTAL
Intervention: Glyco A cream (12% glycolic acid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kefrane cream (0.05% retinoic acid)
Number of subjects: 40
Study: 9296416

Group type: EXPERIMENTAL
Intervention: PCA morphine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PCA meperidine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (bottle-fed infants)
Number of subjects: 102
Study: 8101046

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 37
Study: 3797105

Group type: EXPERIMENTAL
Intervention: Increased plasma L-phenylalanine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Decreased plasma L-phenylalanine
Number of subjects: 8
Study: 31733181

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 145
Study: 29882228

Group type: EXPERIMENTAL
Intervention: Metacognitions Questionnaire‐30 (MCQ‐30)
Number of subjects: 185
Study: 26903605

Group type: EXPERIMENTAL
Intervention: Intralesional pentamidine (120 μg/mm² lesion area, 3 injections over 5 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intralesional pentamidine (240 μg/mm², 3 injections)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intralesional therapy with antimony (3 injections over 5 days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intralesional therapy with antimony (5 injections over 11 days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intralesional therapy with antimony (5 injections)
Number of subjects: 150
Study: 25175935

Group type: EXPERIMENTAL
Intervention: Um RSA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RSAcore
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elementary geometrical shape RSA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Marker-based RSA
Number of subjects: 50
Study: 22901986

Group type: EXPERIMENTAL
Intervention: Soybean oil diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fish oil diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Palm oil diet
Number of subjects: 24
Study: 20042934

Group type: EXPERIMENTAL
Intervention: Online counseling intervention (experimental group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (access to Internet-ready computer and 1 year of Internet service without online counseling)
Number of subjects: 79
Study: 18287130

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 mcg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15947223

Group type: EXPERIMENTAL
Intervention: Transbond Plus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intact
Number of subjects: 30
Study: 15200038

Group type: EXPERIMENTAL
Intervention: Transdermal treatment (n = 52)
Number of subjects: 89

Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate ointment (n = 37)
Number of subjects: 89
Study: 11346391

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Tap/Biopsy
Number of subjects: 420
Study: 9209220

Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate 50 mg/kg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 7959548

Group type: EXPERIMENTAL
Intervention: Blood transfusion (perioperatively)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Transfused patients
Number of subjects: 644
Study: 3115667

Group type: EXPERIMENTAL
Intervention: Voluntary copying of stimulated breathing pattern
Number of subjects: 6

Group type: COMPARATOR
Intervention: Stimulated breathing
Number of subjects: 6
Study: 31971952

Group type: EXPERIMENTAL
Intervention: Educore intervention (informative intervention arm)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 411
Study: 29454389

Group type: EXPERIMENTAL
Intervention: Intervention using intervention mapping (IM) framework with five educational modules and technical assistance calls
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 27430394

Group type: EXPERIMENTAL
Intervention: Anma therapy (Japanese massage, AMT), 40-min session per week for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: No AMT (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anma therapy (Japanese massage, AMT), single session
Number of subjects: 40
Study: 24633595

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise during chemotherapy (n = 78)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Resistance exercise during chemotherapy (n = 82)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care (control group, n = 82)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Overall survival (exercise groups combined)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Distant DFS (exercise groups combined)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Recurrence-free interval (exercise groups combined)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for overweight/obese women
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for stage II/III cancer
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for estrogen receptor-positive tumors
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for HER2-positive tumors
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for taxane-based chemotherapies
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for patients receiving ≥85% of planned chemotherapy
Number of subjects: 242
Study: 22533660

Group type: EXPERIMENTAL
Intervention: Intensive treatment with SBP target <130 mm Hg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard treatment with SBP target <140 mm Hg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normotensive individuals
Number of subjects: 43
Study: 21109302

Group type: EXPERIMENTAL
Intervention: Statin treatment (mainly atorvastatin 24 mg per day)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Usual care (no statin treatment)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Statin treatment (mainly atorvastatin)
Number of subjects: 437
Study: 18221430

Group type: EXPERIMENTAL
Intervention: CoZmonitor Blood Glucose Module
Number of subjects: 34

Group type: COMPARATOR
Intervention: FreeStyle Flash meter (Control)
Number of subjects: 34
Study: 16463007

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg daily (men and premenopausal women) / 10 mg daily (postmenopausal women)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg daily / 10 mg daily
Number of subjects: 163
Study: 12651757

Group type: EXPERIMENTAL
Intervention: Turbuhaler with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: pMDI connected to Nebuhaler spacer with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Turbuhaler and pMDI+Nebuhaler
Number of subjects: 112
Study: 10917257

Group type: EXPERIMENTAL
Intervention: Audio biofeedback
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional bathroom scale method (without audio biofeedback)
Number of subjects: 6
Study: 8866702

Group type: EXPERIMENTAL
Intervention: GHB, 15 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GHB, 30 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GHB (both dosages)
Number of subjects: 8
Study: 1502480

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg or 800 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30415039

Group type: EXPERIMENTAL
Intervention: Ki‐67 labeling index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunohistochemical cytocolorimetric index (ICI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of ICI values with time before relapse
Number of subjects: 0
Study: 28114204

Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peels combined with a modified Kligman formula (MKF) containing hydroquinone 2%, tretinoin 0.05%, and hydrocortisone 1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Modified Kligman formula (MKF) alone
Number of subjects: 30
Study: 25773149

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) 20,000 IU/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24515923

Group type: EXPERIMENTAL
Intervention: Anklebot training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Passive manual stretching
Number of subjects: 34
Study: 23067363

Group type: EXPERIMENTAL
Intervention: Cytokine levels in chronic hepatitis C (TNF‐α, IL‐10, IL‐18)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cytokine levels in chronic hepatitis B (IL‐10)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of TNF‐α with Ishak score or fibrosis in CHB and CHC
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cytokine levels in control group
Number of subjects: 100
Study: 20234783

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus amlodipine 5 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg plus amlodipine 5 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Amlodipine monotherapy
Number of subjects: 221
Study: 18092240

Group type: EXPERIMENTAL
Intervention: Gatekeeper training programme in 32 schools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population-based preventive interventions
Number of subjects: 0
Study: 15903360

Group type: EXPERIMENTAL
Intervention: Creatine alone (Cr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined creatine and carbohydrate (Cr + CHO)
Number of subjects: 10
Study: 12209034

Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study: 9796796

Group type: EXPERIMENTAL
Intervention: Interior design alternatives of a high-speed train
Number of subjects: 0
Study: 7609111

Group type: EXPERIMENTAL
Intervention: Ultrasonic surgical system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy without ultrasonic surgical system
Number of subjects: 16
Study: 2236453

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 636967

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 4

Group type: COMPARATOR
Intervention: Mirror feedback
Number of subjects: 4
Study: 31122600

Group type: EXPERIMENTAL
Intervention: Metoprolol (POST)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (POST2)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 27979038

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow‐derived ALDHbr stem cells
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 82
Study: 25769960

Group type: EXPERIMENTAL
Intervention: Tai-chi group-based exercise program (60 minutes, twice weekly for 48 weeks)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Seated group-based flexibility exercise program (control)
Number of subjects: 503
Study: 23761102

Group type: EXPERIMENTAL
Intervention: HP 2‐2 genotype
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 1303

Group type: COMPARATOR
Intervention: HP 2‐1 and 1‐1 genotypes
Number of subjects: 1303
Study: 22118002

Group type: EXPERIMENTAL
Intervention: Thalidomide combined with bortezomib-dexamethasone (TBD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vincristine-doxorubicin-dexamethasone (T-VAD)
Number of subjects: 46
Study: 19620850

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once daily at night for 12 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 16399263

Group type: EXPERIMENTAL
Intervention: Related prime (e.g. 'piano')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual display with auditory input
Number of subjects: 0
Study: 15546515

Group type: EXPERIMENTAL
Intervention: Virtual outreach group (joint teleconsultation via videolink)
Number of subjects: 2094

Group type: COMPARATOR
Intervention: Standard outpatient appointments
Number of subjects: 2094

Group type: EXPERIMENTAL
Intervention: Virtual outreach group
Number of subjects: 2094
Study: 10907154

Group type: EXPERIMENTAL
Intervention: Direct parental education (DPE) - 10 sessions
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Video parental education (VPE) - standardized video education at home
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (CG) - dermatological standard treatment
Number of subjects: 47
Study: 9310109

Group type: EXPERIMENTAL
Intervention: Eltenac gel
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Oral diclofenac
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 290
Study: 8376682

Group type: EXPERIMENTAL
Intervention: Oral milrinone with converting enzyme inhibitors
Number of subjects: 254
Study: 3795265

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior modification intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30073496

Group type: EXPERIMENTAL
Intervention: Long biliopancreatic limb Roux-en-Y gastric bypass (LBP-GB) with BPL 150 cm, alimentary limb 75 cm
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard Roux-en-Y gastric bypass (S-GB) with BPL 75 cm, alimentary limb 150 cm
Number of subjects: 146
Study: 27473306

Group type: EXPERIMENTAL
Intervention: High-dose (HD) influenza vaccine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard-dose (SD) influenza vaccine
Number of subjects: 105
Study: 25636721

Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Physical activity (measured as hours/day)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Sitting (measured as hours/day)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Intake of fish
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Calcium supplement intake
Number of subjects: 566
Study: 23972968

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg QD
Number of subjects: 5041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5041
Study: 21910510

Group type: EXPERIMENTAL
Intervention: Fimasartan 240 mg (fed state)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fimasartan 20-480 mg (fasted single doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg (fasted repeated doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fimasartan 360 mg (fasted repeated doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fimasartan (various doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fimasartan (240 mg in fed state)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18164612

Group type: EXPERIMENTAL
Intervention: SRL172
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IL-2 plus SRL172
Number of subjects: 96

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 96
Study: 16923246

Group type: EXPERIMENTAL
Intervention: Low-dose antioxidant supplementation (nutritional doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 12654439

Group type: EXPERIMENTAL
Intervention: Pd-103 (125 Gy)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: I-125 (144 Gy)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Pd-103 (90 Gy) with 44 Gy EBRT
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Pd-103 (115 Gy) with 20 Gy EBRT
Number of subjects: 220

Group type: COMPARATOR
Intervention: Beam radiation (44 Gy)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Beam radiation (20 Gy)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Beam radiation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Full dose Pd-103
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: No instances of rectal ulceration or fistula reported
Number of subjects: 220
Study: 10600654

Group type: EXPERIMENTAL
Intervention: Adenosine (70 microg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Theophylline (5 mg/kg body weight)
Number of subjects: 20
Study: 9170400

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 631

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 631
Study: 1301267

Group type: EXPERIMENTAL
Intervention: Phenol mucilage (PM)
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Phenol-atabrine paste (PAP)
Number of subjects: 1705
Study: 3942496

Group type: EXPERIMENTAL
Intervention: 12 hours of antibiotics
Number of subjects: 116

Group type: COMPARATOR
Intervention: 5 days of antibiotics
Number of subjects: 116
Study: 30177406

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy with 50Hz frequency, low intensity of 20Gauss, combined with Conventional physical therapy Protocol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional physical therapy Protocol
Number of subjects: 50
Study: 28347663

Group type: EXPERIMENTAL
Intervention: Smartphone
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pager
Number of subjects: 205
Study: 25534298

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan exercise sessions (Yang style) twice a week for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 36
Study: 22893563

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg daily
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study: 20974993

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gatorade (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined treatments (orange juice and grapefruit juice)
Number of subjects: 24
Study: 19250072

Group type: COMPARATOR
Intervention: Anatomical approach (group A)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Integrated approach (group B)
Number of subjects: 97
Study: 17157434

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.1mg) injected submucosally at the urethrotomy site
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (internal urethrotomy without mitomycin C)
Number of subjects: 40
Study: 15975061

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14613569

Group type: EXPERIMENTAL
Intervention: Efalizumab (weekly subcutaneous administration)
Number of subjects: 1095
Study: 9792934

Group type: EXPERIMENTAL
Intervention: Continuous high-dose IL-2 infusion combined with CTX-based chemotherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Triple chemotherapy (CTX, etoposide and Ara-C)
Number of subjects: 15